Receiving a cancer diagnosis is one of the most terrifying experiences someone can have. Unfortunately, with one in nine men suffering from prostate cancer in his lifetime, many of us personally know someone who has been diagnosed, will be diagnosed, or is currently undergoing treatment for this condition.
In honor of September’s Prostate Cancer Awareness Month, we want to bring attention to more than just the fact that regular prostate exams can help diagnose the condition, and there’s a lot more to know about the disease that can help patients make informed decisions about their care during this scary time.
The good news is prostate cancer is highly treatable and there are several options available based on the person’s age, health and personal preference.
About Steven Finkelstein
Steven Eric Finkelstein received his M.D. from the University of Michigan in 1997 graduating cum laude eruditions causa. He joined the National Cancer Institute (NCI), National Institutes of Health (NIH) as Clinical Associate in 1999 and completed both Surgical Oncology Fellowship as well as Clinical Immunotherapy Fellowship in 2004. Following completion of an additional radiation oncology residency, Dr. Finkelstein was selected as Chief Resident in Radiation Oncology at Moffitt Cancer Center / University of South Florida. In 2011, he was recruited to join the 21C Translational Research Consortium (TRC) and was appointed its National Director. In 2014, he was promoted to 21C Chief Science Officer. In 2017, he returned to Florida to serve as Cancer Director of Bay Regional Cancer Center at AUI, and in 2019 Dr. Finkelstein joined the US Oncology Network at Florida Cancer Affiliates
Dr. Finkelstein has a special interest in the study and patient care and research of a variety of cancers, using radiation driven, and personalized systemic therapy. Accordingly, he holds three International patents pending in the field of “cutting edge” technologies.
Dr. Finkelstein has given national and international lectures, published numerous professional journal articles and written book chapters, resulting in over 8000 reference citations. He also serves on the editorial board of key international journals including the American Society of Clinical Oncology (ASCO) as the ASCO Associate Editor for Immunotherapy.
For these contributions to patients, Dr. Finkelstein was one of the youngest physicians to receive accelerated fellowship in the American College of Radiation Oncology (ACRO) in 2017 and elected to the ACRO Board of Chancellors and Chair of Education in 2018.